Treatment Response and Survival in Methamphetamine‐Associated Pulmonary Arterial Hypertension
Journal of the American Heart Association · 04.11.2025 · 14 (21)
DOI: 10.1161/jaha.125.042673 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 04.11.2025. Verfasst von Cole Uhland und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Allergy, Critical Care3 and Sleep Medicine University of Arizona Tucson AZ. Hauptthemen laut MEDLINE: Methamphetamine, Epoprostenol, Antihypertensive Agents, Pulmonary Arterial Hypertension. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
Background
Methamphetamine‐associated pulmonary arterial hypertension (Meth‐PAH) represents a growing subset of PAH. Relative to idiopathic PAH (iPAH), it is unknown whether patients with Meth‐PAH treated with continuous prostacyclin have similar outcomes and treatment response. The aims of this analysis are to evaluate survival, response to therapy, and right ventricle function in similarly treated patients with Meth‐PAH and iPAH.
Methods
A prospective protocolized cohort of 138 incident patients (64 Meth‐PAH, 74 iPAH) was followed longitudinally, with all patients being treatment‐naïve at baseline. Hemodynamic assessments, cardiac imaging, and response to therapy were evaluated. A standardized therapeutic approach involving parenteral subcutaneous treprostinil was applied. Survival was analyzed using Kaplan–Meier and Cox regression.
Results
Both groups had similarly advanced PAH at presentation. Improvement in hemodynamics and reduction in European Respiratory Society risk scores were seen over the course of follow‐up in both groups. Twenty‐nine of 64 (45%) Meth‐PAH and 51/74 (69%) of iPAH were initiated on parenteral prostacyclin. During treatment, only 4 patients (2 iPAH and 2 meth‐PAH) were taken off treprostinil because of safety concerns. Transplant‐free survival was 54/64 (84.4%) for meth‐PAH over a mean follow‐up time of 46 months and 54/74 (72.9%) for iPAH over a mean follow‐up time of 67 months. Additionally, continued methamphetamine use did not adversely affect disease progression or mortality.
Conclusions
Among Meth‐PAH patients treated with an aggressive parenteral prostacyclin strategy, there is not a large difference in mortality and treatment response to iPAH. Further research is warranted to explore the long‐term effects of methamphetamine use on PAH pathogenesis and outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pulmonary, Allergy, Critical Care3 and Sleep Medicine University of Arizona Tucson AZ.
- Division of Pulmonary, Allergy, Critical Care and Sleep Medicine Legacy Health System Portland OR.
- Divison of Cardiology University of Arizona Tucson AZ.
ORCID-Profile: Cole Uhland, Franz P Rischard
Förderung
- NHLBI NIH HHS
Zitieren
APA
Uhland, C., Gibbs, A., Insel, M., Kubba, S., & Rischard, F. P. (2025). Treatment Response and Survival in Methamphetamine‐Associated Pulmonary Arterial Hypertension. Journal of the American Heart Association, 14(21). https://doi.org/10.1161/jaha.125.042673
Vancouver
Uhland C, Gibbs A, Insel M, Kubba S, Rischard FP. Treatment Response and Survival in Methamphetamine‐Associated Pulmonary Arterial Hypertension. Journal of the American Heart Association. 2025;14(21). doi:10.1161/jaha.125.042673
BibTeX
@article{Uhland2025,
author = {Uhland, Cole and Gibbs, Angela and Insel, Michael and Kubba, Saad and Rischard, Franz P},
title = {Treatment Response and Survival in Methamphetamine‐Associated Pulmonary Arterial Hypertension},
journal = {Journal of the American Heart Association},
year = {2025},
volume = {14},
number = {21},
doi = {10.1161/jaha.125.042673}
}
EUVIMED